Treatment of a prostate cancer cell line with NKp30-Ig reduced cancer growth, and macrophages activated against NKp30-Ig-coated cells mediated antibody-dependent cell cytotoxicity (ADCC) [79]. Here, NCR3 is linked to prostate carcinoma.